AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06451692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pharmacist
Description: The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
Study NCT06051318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast A
Description: Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
Study NCT06051318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast B
Description: Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
Study NCT05721352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Nature scene plus heart rate variability biofeedback phone application
Description: phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
Study NCT05151692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.
Study NCT04905797 — intervention group
Intervention type: OTHER
Intervention: World Health Organizations Disability Assessment Schedule (WHODAS 2.0)
Description: Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
Study NCT05302167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Molehill Mountain app
Description: The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study.
Study NCT05302167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molehill Mountain app
Description: As above.
Study NCT05591859 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration Anatomic Acetabular Shell
Description: Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
Study NCT06401694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-delivered meals
Description: Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
Study NCT06401694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-delivered meals
Description: Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
Study NCT06401694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness check and socialization visit
Description: At-home delivery with opportunity for driver observation and interaction
Study NCT06401694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness check and socialization visit
Description: At-home delivery with opportunity for driver observation and interaction
Study NCT06401694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker calls
Description: Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
Study NCT06401694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental grocery bag
Description: Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
Study NCT06402955 — intervention group
Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: Radiotracer for imaging.
Study NCT06435416 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05673200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05673200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05673200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05673200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Personality Inventory for DSM-5 (PID-5)
Description: Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
Study NCT05673200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05673200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05673200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06534125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo self-administered acupressure therapy to planned pressure points
Study NCT06534125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy with acupuncture needles applied to planned pressure points
Study NCT06534125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Receive SOC AI therapy
Study NCT06534125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibition Therapy
Description: Receive SOC AI therapy
Study NCT06534125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies
Study NCT06534125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06534125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04915183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
Study NCT04915183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
Study NCT04738643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Use Treatment Service and Varenicline Management
Description: The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task (CANTAB)
Description: The estimate of time where an individual can successfully inhibit their responses 50% of the time.
Study NCT06554535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab，Platinum-based Chemotherapy，Aspirin
Description: Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
Study NCT05133531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered Intravenous (IV) per the protocol
Study NCT04500392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
Study NCT04500392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula
Description: Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
Study NCT05431387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study NCT05431387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo
Study NCT05431387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
Study NCT05431387 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
Study NCT04641728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg every three weeks (Q3W)
Study NCT04641728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib 300 mg twice daily (BID)
Study NCT05133531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered IV and subcutaneous (SC) per the protocol
Study NCT05133531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per the protocol
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-Extra Dimensional Set Shift (CANTAB)
Description: 1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached.
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spatial Working Memory Test (CANTAB)
Description: 1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more.
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multitasking Test (CANTAB)
Description: 1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information.
Study NCT04798131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active neurofeedback procedure
Description: Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
Study NCT04798131 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback procedure
Description: Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
Study NCT05444257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT05133531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Administered IV per the protocol
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cambridge Gambling Task Test
Description: 1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition.
Study NCT04826822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone + Dexamethasone
Description: Low doses of orally administered spironolactone and dexamethasone
Study NCT04826822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care SARS-CoV-2 treatment
Description: Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
Study NCT05980559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: 50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
Study NCT05519475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: Administered by subcutaneous injection (SC)
Study NCT05519475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study NCT06314672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accrual
Description: Participate in AEP
Study NCT06314672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in implementation discussions
Study NCT06314672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Participate in educational sessions/activities
Study NCT05279300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS5001
Description: CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
Study NCT06352918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmar grasp reflex stimulation
Description: This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
Study NCT06228599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Plan
Description: A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
Study NCT06314672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo interview
Study NCT06314672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review
Description: Undergo data capture review
Study NCT06314672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05159427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucotrol XL 5Mg Extended-Release Tablet
Description: Participants are randomized to take one tablet of this study drug by mouth.
Study NCT05159427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide ER 5 MG 24 HR Extended Release Oral Tablet
Description: Participants are randomized to take one tablet of this study drug by mouth.
Study NCT05159427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 200Mg Tab
Description: Participants will take one tablet of this study drug by mouth.
Study NCT05159427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C6-Glipizide
Description: Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
Study NCT06257472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
Study NCT06257472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Headset
Description: Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
Study NCT05630703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Attention Training in IBS
Description: The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
Study NCT05630703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
Study NCT06472414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Counselling Sessions
Description: Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
Study NCT06472414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Women-Focused Sessions
Description: Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.